The future is "orphan"!? - SKC at the 8th Orphan Drug Congress, 13-15 November, in Barcelona

Fri, 2017 / 11 / 03
Which specific issues need to be addressed in orphan drug pricing and reimbursement strategies? Which regulatory (country-specific) particularities should be considered in the context of drugs for rare diseases? Which success factors are decisive for the negotiation of the reimbursement amount? Which future strategic challenges must stakeholder react to?

These and other questions are part of the discussion of the interactive round table "Effective strategies for setting drug prices and achieving reimbursement of orphan drugs" under the direction of Prof. Dr. Matthias P. Schönermark, Managing Director of SKC Consulting.

As a leading German healthcare consulting firm with many years of extensive expertise in strategic issues, we look forward to inspiring and horizon-expanding discussions in an international environment.

Get one of the last tickets and join us on 14th November in the beautiful coastal city of Barcelona!

For registration and further information, please note the following links: http://www.terrapinn.com/conference/world-orphan-drug-congress/index.stm?_ga=2.103188288.1168108668.1509697174-649871901.1509697174
to the top